Translating neuroimaging findings from research into clinical practice (PSYSCAN): Clinical High Risk
- Conditions
- high risk of psychosisschizophrenia10039628
- Registration Number
- NL-OMON47887
- Lead Sponsor
- Institute of Psychiatry, King's College, London
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 74
* 16-40 years old
* Written informed consent of subjects aged 18 to 40 years
* Written informed consent of parents and/or legal guardians for subjects aged
16 or 17, in
addition to assent from the minor subject, following local laws and regulations
Participants at high risk of psychosis will be evaluated using a quantitative
clinical tool that
assesses:
* Inclusion into one of three groups as assessed by the Comprehensive
Assessment of At-Risk Mental States (CAARMS version 2006):
i) vulnerability group,
ii) attenuated psychosis group,
iii) brief intermittent psychosis symptoms group.
* Any previous neurosurgery or neurological disorder, including epilepsy
* History of head injury resulting in unconsciousness lasting at least 1 hour
* Pregnancy
* Any contraindications for MRI
* Refusing to have blood drawn and/or MRI performed
* Subject is unable to fully comprehend the purpose of the study or make a
rational
decision whether or not to participate
* Estimate of IQ < 70
* Antipsychotic medication for > 30 days (cumulative number of days) in the 3
months
before the baseline assessments (including self-ratings and screening
assessments), at
doses that would be adequate for treating a first episode of psychosis (i.e.
excludes very
low doses)
* Any past episode of frank psychosis lasting > 7 days
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method